Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01610180 | Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | completed | Phase 2 | 18 | Fondazione Progetto EmatologiaOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01526694 | Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | completed | Phase 2 | 30 | Azienda Ospedaliera di BolzanoOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00119392 | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 42 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | completed | Phase 1 / Phase 2 | 64 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT01985126 | An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD | completed | Phase 2 | 124 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT01478048 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 185 | Bristol-Myers SquibbINDUSTRY | 5 | May 21, 2018 | clinicaltrials |
| NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | completed | Phase 2 | 36 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01558167 | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia(CLL2P) | completed | Phase 1 / Phase 2 | 22 | German CLL Study GroupOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | Phase 2 | 101 | AmgenINDUSTRY | 2 | May 14, 2018 | clinicaltrials |
| NCT00274963 | Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | German CLL Study GroupOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00275015 | Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | completed | Phase 2 | 169 | German CLL Study GroupOTHER | 2 | May 11, 2018 | clinicaltrials |
| NCT00794820 | Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline | completed | Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2018 | clinicaltrials |
| NCT01191190 | Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)(CRC027) | completed | Phase 2 | 21 | Januario Castro, M.D.OTHER | 1 | May 8, 2018 | clinicaltrials |
| NCT00574288 | Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | completed | Phase 2 | 104 | Janssen Research & Development, LLCINDUSTRY | 4 | Apr 27, 2018 | clinicaltrials |
| NCT01263704 | A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01030536 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | completed | Phase 1 / Phase 2 | 23 | MedImmune LLCINDUSTRY | 2 | Apr 9, 2018 | clinicaltrials |
| NCT01651039 | Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | completed | Phase 2 | 32 | Ajai ChariOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02791373 | Vinorelbine and Gemcitabine in Myeloma(ViGeM) | completed | Phase 2 | 136 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03485118 | RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma(Hi-CHOP) | completed | Phase 2 | 137 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 0 | Apr 2, 2018 | clinicaltrials |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 48 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 27, 2018 | clinicaltrials |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | completed | Phase 1 / Phase 2 | 45 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | Mar 27, 2018 | clinicaltrials |
| NCT00398710 | A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia | completed | Phase 2 | 37 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01515176 | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | completed | Phase 1 / Phase 2 | 177 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 65 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00201877 | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00963534 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.(LENA-BERIT) | completed | Phase 1 / Phase 2 | 51 | Lund University HospitalOTHER | 4 | Mar 12, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT01622439 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma(VALFRID) | completed | Phase 1 / Phase 2 | 50 | Lund University HospitalOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01737177 | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL(R2-B) | completed | Phase 2 | 42 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT01547806 | Collection of Transplant Stem Cells for Plasma Cell Myeloma | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00253630 | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2018 | clinicaltrials |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | Phase 1 / Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00287872 | Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00375791 | Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | completed | Phase 2 | 67 | AEterna ZentarisINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00401011 | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 84 | AEterna ZentarisINDUSTRY | 0 | Feb 23, 2018 | clinicaltrials |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | completed | Phase 2 | 13 | Incyte CorporationINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01181258 | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | completed | Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02294552 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | completed | Phase 2 | 200 | Ivan S MoiseevOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02363439 | Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 | completed | Phase 1 / Phase 2 | 5 | Idera Pharmaceuticals, Inc.INDUSTRY | 0 | Jan 9, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01270932 | Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2018source: clinicaltrials